ATE132532T1 - Expression von tetanustoxinfragment c - Google Patents

Expression von tetanustoxinfragment c

Info

Publication number
ATE132532T1
ATE132532T1 AT90909052T AT90909052T ATE132532T1 AT E132532 T1 ATE132532 T1 AT E132532T1 AT 90909052 T AT90909052 T AT 90909052T AT 90909052 T AT90909052 T AT 90909052T AT E132532 T1 ATE132532 T1 AT E132532T1
Authority
AT
Austria
Prior art keywords
fragment
expression
tetanustoxin
tetanus toxin
mature fragment
Prior art date
Application number
AT90909052T
Other languages
English (en)
Inventor
Neil Fraser Fairweather
Andrew Joseph Makoff
Original Assignee
Evans Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans Medical Ltd filed Critical Evans Medical Ltd
Application granted granted Critical
Publication of ATE132532T1 publication Critical patent/ATE132532T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90909052T 1989-06-20 1990-06-20 Expression von tetanustoxinfragment c ATE132532T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914122A GB8914122D0 (en) 1989-06-20 1989-06-20 Polypeptide expression

Publications (1)

Publication Number Publication Date
ATE132532T1 true ATE132532T1 (de) 1996-01-15

Family

ID=10658724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909052T ATE132532T1 (de) 1989-06-20 1990-06-20 Expression von tetanustoxinfragment c

Country Status (9)

Country Link
US (1) US5443966A (de)
EP (1) EP0478602B1 (de)
JP (1) JP2981286B2 (de)
AT (1) ATE132532T1 (de)
DE (1) DE69024652T2 (de)
DK (1) DK0478602T3 (de)
ES (1) ES2084030T3 (de)
GB (1) GB8914122D0 (de)
WO (1) WO1990015871A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601826A (en) * 1989-06-30 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
WO1994000487A1 (en) * 1992-06-30 1994-01-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
GB9401787D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
CA2244228A1 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
WO1997035612A1 (fr) 1996-03-23 1997-10-02 The Research Foundation For Microbial Diseases Of Osaka University Antigene a fragment fonctionnel de la toxine du tetanos, et vaccin contre le tetanos
US5958469A (en) * 1997-05-14 1999-09-28 Eastman Kodak Company Method for fabricating tools for molding diffractive surfaces on optical lenses
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
DE69836982T2 (de) * 1997-08-14 2007-10-31 Institut Pasteur Hybride Tetanustoxinproteine die retrograd und transsynaptisch ins ZNS migrieren
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
DK1296715T4 (en) 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
MXPA05014016A (es) * 2003-06-23 2006-03-17 Baxter Int Proteinas portadoras para vacunas.
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
EP1790358A1 (de) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2553102B1 (de) 2010-03-30 2015-12-09 Pfenex Inc. Hochleistungs-expression rekombinanter toxinproteine
EP2569018A4 (de) 2010-05-14 2013-12-04 Philadelphia Children Hospital Humanisiertes ttc und verfahren zu seiner verwendung
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN105007936B (zh) 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
US20170151316A1 (en) 2014-07-02 2017-06-01 Spherium Biomed, S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen

Also Published As

Publication number Publication date
US5443966A (en) 1995-08-22
EP0478602A1 (de) 1992-04-08
GB8914122D0 (en) 1989-08-09
DK0478602T3 (da) 1996-02-05
ES2084030T3 (es) 1996-05-01
EP0478602B1 (de) 1996-01-03
JP2981286B2 (ja) 1999-11-22
DE69024652D1 (de) 1996-02-15
JPH04506005A (ja) 1992-10-22
WO1990015871A1 (en) 1990-12-27
DE69024652T2 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
DE69024652D1 (de) Expression von tetanustoxinfragment c
FR2646437B1 (fr) Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK0652758T3 (da) Diferitoxin-vacciner
ATE195347T1 (de) Methoden der erhöhung der sekretion von überexpremierten proteinen
ATE93271T1 (de) Vakzine.
DK0575443T3 (da) Ærteproteinhydrolysat, fremgangsmåde til dets fremstilling og anvendelse deraf
NO961812D0 (no) Humanproteaseinhibitorer av Kunitz-type
ATE41034T1 (de) Herstellung von protein a.
FI952148L (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
ATE162311T1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
ES538000A0 (es) Un procedimiento para obtener un adn que codifica un factor de necrosis de tumor de conejo
ATE81136T1 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
ES8704975A1 (es) Un procedimiento para preparar un polipeptido que se puede utilizar en una vacuna para proteger seres humanos contra infeccion por plasmodium falciparum
ES8506194A1 (es) Polipeptido de interferon- humano
ATE194624T1 (de) Mutanten von menschlichem antithrombin iii
NO913078L (no) Oekt proteinproduksjon i dyr.
ATE106744T1 (de) Neue methode zur induzierung der ovulation beim menschen.
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
ATE126794T1 (de) Verfahren zur herstellung von formyltetrahydropyranen.
DE69004199D1 (de) Herstellung von Cymenol durch direkte Dehydrogenierung.
NO843750L (no) Immuninterferon og fremgangsmaate ved fremstilling derav
ES529479A0 (es) Un procedimiento para producir un compuesto de antraciclina
ATE231887T1 (de) Protein mit anti-tumorwirkung
DK0592574T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner og værtsceller anvendt derved

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time